English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Due to the poor immunogenicity of subunit protein antigens, there is a needto use adjuvants in order to generate effective immune responses. Basic fibroblastgrowth factor (bFGF) is one of the best characterized pro-angiogenic cytokineand is a candidate target for anticancer therapy. We used truncated bFGF (tbFGF)combined with engineered pVAX-nCpG as novel adjuvant to immunize mice in orderto inhibit tumor angiogenesis and suppress tumor growth. In our study, the resultsdemonstrated that the mice immunized with tbFGF-alum-pVAX-8CpG produced a bettertumor-suppression effect compared with the other groups, apart from the grouptreated with tbFGF-alum-CpG. In addition, the function of immune modulation ofpVAX-8CpG was similar to CpG ODNs. The vaccine composed of tbFGF, alum and pVAX-8CpGeffectively inhibited tumor angiogenesis and induced strong antitumor immune responses.The antitumor activity induced by the vaccine tbFGF-alum-pVAX-8CpG was not onlyassociated with the antigen-specific antibody, but also with the killing activityof cytotoxic cells. This indicates that alum-pVAX-8CpG may be an innovative adjuvantfor cancer vaccines.

molecular medicine reports

bFGF peptide combined with the pVAX-8CpG plasmid as adjuvant is a novel anticancer vaccine inducing effective immune responses against Lewis lung carcinoma